Verrica Pharmaceuticals Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Verrica Pharmaceuticals Inc. (VRCA) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$9.54 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2025-08-12
- Verrica Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was $204.00K.
- Verrica Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$9.74M.
- Verrica Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was -$16.20M.
- Verrica Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$22.86M.
- Verrica Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$76.58M.
- Verrica Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$67.00M.
- Verrica Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$24.49M.
- Verrica Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$35.08M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-06-30 | $204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$9.54M 10-Q · filed 2025-08-12 | -$25.74M derived: sum of 3 quarters · filed 2025-08-12 | -$48.60M derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | -$9.74M 10-Q · filed 2025-05-13 | -$25.94M derived: sum of 2 quarters · filed 2025-05-13 | -$48.80M derived: sum of 3 quarters · filed 2025-05-13 | -$65.99M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-12-31 | -$16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$39.06M derived: sum of 2 quarters · filed 2025-03-11 | -$56.25M derived: sum of 3 quarters · filed 2025-08-12 | -$76.58M 10-K · filed 2025-03-11 |
| 2024-09-30 | -$22.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$40.05M derived: sum of 2 quarters · filed 2025-08-12 | -$60.38M 10-Q · filed 2024-11-05 | -$84.99M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-06-30 | -$17.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$37.52M 10-Q · filed 2025-08-12 | -$62.13M derived: sum of 3 quarters · filed 2025-08-12 | -$86.93M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$20.33M 10-Q · filed 2025-05-13 | -$44.95M derived: sum of 2 quarters · filed 2025-05-13 | -$69.75M derived: sum of 3 quarters · filed 2025-05-13 | -$80.74M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$24.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$49.42M derived: sum of 2 quarters · filed 2025-03-11 | -$60.41M derived: sum of 3 quarters · filed 2025-03-11 | -$67.00M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$24.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$35.79M derived: sum of 2 quarters · filed 2024-11-05 | -$42.38M 10-Q · filed 2024-11-05 | -$48.31M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$10.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$17.58M 10-Q · filed 2024-08-14 | -$23.51M derived: sum of 3 quarters · filed 2024-08-14 | -$23.43M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$6.59M 10-Q · filed 2024-05-13 | -$12.52M derived: sum of 2 quarters · filed 2024-05-13 | -$12.44M derived: sum of 3 quarters · filed 2024-05-13 | -$22.61M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$5.85M derived: sum of 2 quarters · filed 2024-02-29 | -$16.02M derived: sum of 3 quarters · filed 2024-02-29 | -$24.49M 10-K · filed 2024-02-29 |
| 2022-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$10.09M derived: sum of 2 quarters · filed 2023-11-09 | -$18.55M 10-Q · filed 2023-11-09 | -$28.09M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$10.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$18.64M 10-Q · filed 2023-08-08 | -$28.18M derived: sum of 3 quarters · filed 2023-08-08 | -$41.01M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$8.47M 10-Q · filed 2023-05-09 | -$18.01M derived: sum of 2 quarters · filed 2023-05-09 | -$30.84M derived: sum of 3 quarters · filed 2023-05-09 | -$42.61M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$9.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$22.37M derived: sum of 2 quarters · filed 2023-03-06 | -$34.14M derived: sum of 3 quarters · filed 2023-03-06 | -$35.08M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$12.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$24.60M derived: sum of 2 quarters · filed 2022-11-07 | -$25.54M 10-Q · filed 2022-11-07 | -$38.52M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$11.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$12.71M 10-Q · filed 2022-08-11 | -$25.69M derived: sum of 3 quarters · filed 2022-08-11 | -$36.17M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$936.00K 10-Q · filed 2022-05-09 | -$13.91M derived: sum of 2 quarters · filed 2022-05-09 | -$24.40M derived: sum of 3 quarters · filed 2022-05-09 | -$33.81M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$12.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | -$23.46M derived: sum of 2 quarters · filed 2022-03-02 | -$32.87M derived: sum of 3 quarters · filed 2022-03-02 | -$42.69M 10-K · filed 2022-03-02 |
| 2020-09-30 | -$10.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$19.89M derived: sum of 2 quarters · filed 2021-11-12 | -$29.72M 10-Q · filed 2021-11-12 | -$37.35M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$9.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$19.23M 10-Q · filed 2021-08-10 | -$26.87M derived: sum of 3 quarters · filed 2021-08-10 | -$32.96M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$9.82M 10-Q · filed 2021-05-07 | -$17.46M derived: sum of 2 quarters · filed 2021-05-07 | -$23.55M derived: sum of 3 quarters · filed 2021-05-07 | -$30.55M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | -$7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$13.73M derived: sum of 2 quarters · filed 2021-03-17 | -$20.73M derived: sum of 3 quarters · filed 2021-03-17 | -$28.21M 10-K · filed 2021-03-17 |
| 2019-09-30 | -$6.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$13.09M derived: sum of 2 quarters · filed 2020-11-09 | -$20.57M 10-Q · filed 2020-11-09 | -$28.15M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$14.48M 10-Q · filed 2020-08-05 | -$22.06M derived: sum of 3 quarters · filed 2020-08-05 | |
| 2019-03-31 | -$7.48M 10-Q · filed 2020-05-07 | -$15.06M derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2018-12-31 | -$7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$20.65M 10-K · filed 2020-03-13 | ||
| 2018-09-30 | -$13.07M 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |